Morten Orebo Holmström

16PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 24, 2026
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Josephine Hallundbæk Ruders, Shamaila Munir Ahmad, Rasmus Erik Johansson Mortensen

|Aug 20, 2024
The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets.

Morten Orebo Holmström, Josephine Hallundbæk Ruders, Caroline Hasselbalch Riley

|Mar 22, 2023
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle

|Jun 15, 2022
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Mathieu Gigoux, Morten O Holmström, Roberta Zappasodi

|Feb 03, 2022
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.

Simone Kloch Bendtsen, Maria Perez-Penco, Mie Linder Hübbe

|Jan 07, 2021
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner.

Morten Orebo Holmström, Rasmus Erik Johansson Mortensen, Angelos Michail Pavlidis

Pageof 3

Frequent Collaborators

9 joint publications

Mads Hald Andersen

4 joint publications

Hans Hasselbalch

3 joint publications

Özcan Met

2 joint publications

Inge Marie Svane